Subject:
- Active Substance: Vericiguat
- Name: Verquvo®
- Therapeutic area: Chronic heart failure
- Pharmaceutical company: Bayer Vital GmbH
Time table:
- Start: 15.09.2021
- Final decision by G-BA: 03.03.2022
Final decision:
- Hint for a minor additional benefit